 | |||||||||
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has engaged Dr. Reuter Investor Relations ("Dr. Reuter") to provide investor awareness and communications services across Germany and the broader European capital markets, effective September 1, 2026.
Dr. Reuter is a recognized European investor relations and financial communications firm with an established network of institutional investors, retail shareholders, and financial media throughout the DACH region and the European Union. The engagement is intended to enhance the Company’s visibility among European investors, support market education regarding its clinical research strategy, and strengthen shareholder communications. Dr. Reuter's business address is Tower 185, Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt, Germany, and the firm may be contacted at e.reuter@dr-reuter.eu.
Under the terms of the agreement, Dr. Reuter will provide investor relations and financial public relations services across European capital markets, including campaign and editorial articles, translation and distribution of press releases, journalist targeting, social media outreach, and ongoing performance reporting. The agreement commences September 1, 2026 and runs for an initial six-month term ending February 28, 2027, at a monthly fee of €6,000, payable in advance. Also, as part of the agreement Dr. Reuter may provide services related to an investor roadshow at an estimated cost of €12,900 per roadshow, payable in advance. The Company expects to engage Dr. Reuter for one roadshow during the term of the agreement.
Following the initial term, the agreement will continue on a month to month basis. Dr. Reuter is arm's length to the Company and, to the knowledge of the Company, holds no securities of the Company.
About NeuroThera Labs Inc.
NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
For further information, please contact:
Michal Efraty
IR Manager
NeuroThera Labs Inc.
Telephone: +972-3-7617108
Email: michal@efraty.com
Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.
In particular, this press release contains forward-looking information regarding, without limitation: (i) the expected services to be provided by Dr. Reuter Investor Relations pursuant to the investor relations and communications agreement; (ii) the anticipated benefits of the engagement, including increased visibility, investor awareness, and shareholder communications across German and broader European capital markets; (iii) the potential outcomes of such engagements, including the development of relationships with institutional investors; and (iv) the Company's broader strategy to expand its presence and positioning within European markets.
Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with pharmaceutical development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.
The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.
Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2026 TheNewswire - All rights reserved.
